Respiratory Syncytial Virus clinical trials

Explore recruiting respiratory syncytial virus clinical trials.

Recruiting respiratory syncytial virus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Respiratory Syncytial Virus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Immunogenicity after a prime dose and revaccination with adjuvanted RSVPreF3 vaccine in the most elderly and frail population – an open-labeled phase IIIb-trial RSV Immunogenicity Study in the Elderly (RISE)

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Pregnant Women, and Safety, and Immunogenicity in Infants Born to Vaccinated Mothers.

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial RSVaxID

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3b, open-label study to evaluate the non-inferiority of the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in adults 18-49 years of age at increased risk of respiratory syncytial virus disease, compared to older adults ≥60 years of age.

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 3b, randomized, open label, multi-country, multi-center, extension and crossover vaccination study to evaluate the immunogenicity and safety of different revaccination schedules and persistence of a single dose of the RSVPreF3 OA vaccine in adults aged 60 years and above who participated in the RSV OA=ADJ-006 study

Germany, Finland, Estonia, Belgium, Poland, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of S-337395 in symptomatic nonhospitalized adults with respiratory syncytial virus who are at high risk of progression to severe disease

Bulgaria, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Respiratory Syncytial Virus trials by city

Respiratory Syncytial Virus in Toronto Respiratory Syncytial Virus in Vancouver Respiratory Syncytial Virus in Montreal Respiratory Syncytial Virus in Calgary Respiratory Syncytial Virus in Edmonton Respiratory Syncytial Virus in Ottawa Respiratory Syncytial Virus in Winnipeg Respiratory Syncytial Virus in Quebec City Respiratory Syncytial Virus in Hamilton Respiratory Syncytial Virus in Kitchener Respiratory Syncytial Virus in London Respiratory Syncytial Virus in Halifax Respiratory Syncytial Virus in New York Respiratory Syncytial Virus in Los Angeles Respiratory Syncytial Virus in Chicago Respiratory Syncytial Virus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease